{"pmid":32344307,"title":"COVID-19 type III hypersensitivity reaction.","text":["COVID-19 type III hypersensitivity reaction.","Med Hypotheses","Mutar Mahdi, Batool","32344307"],"journal":"Med Hypotheses","authors":["Mutar Mahdi, Batool"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344307","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.mehy.2020.109763","topics":["Mechanism","Treatment"],"weight":1,"_version_":1665351883931254785,"score":8.574329,"similar":[{"pmid":32333915,"title":"Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2.","text":["Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2.","Underlying respiratory allergy and experimental allergen exposure reduce the expression of the SARS-CoV-2 receptor, ACE2, which could lead to reduced COVID-19 susceptibility.","J Allergy Clin Immunol","Jackson, Daniel J","Busse, William W","Bacharier, Leonard B","Kattan, Meyer","O'Connor, George T","Wood, Robert A","Visness, Cynthia M","Durham, Stephen R","Larson, David","Esnault, Stephane","Ober, Carole","Gergen, Peter J","Becker, Patrice","Togias, Alkis","Gern, James E","Altman, Mathew C","32333915"],"abstract":["Underlying respiratory allergy and experimental allergen exposure reduce the expression of the SARS-CoV-2 receptor, ACE2, which could lead to reduced COVID-19 susceptibility."],"journal":"J Allergy Clin Immunol","authors":["Jackson, Daniel J","Busse, William W","Bacharier, Leonard B","Kattan, Meyer","O'Connor, George T","Wood, Robert A","Visness, Cynthia M","Durham, Stephen R","Larson, David","Esnault, Stephane","Ober, Carole","Gergen, Peter J","Becker, Patrice","Togias, Alkis","Gern, James E","Altman, Mathew C"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333915","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaci.2020.04.009","keywords":["ace2 expression","covid-19","sars-cov-2","allergic sensitization","asthma","receptor","respiratory allergy"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1665071049662791680,"score":68.198204},{"pmid":32153144,"pmcid":"PMC7113449","title":"COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis.","text":["COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis.","Infect Chemother","Song, Young Goo","Shin, Hyoung Shik","32153144"],"journal":"Infect Chemother","authors":["Song, Young Goo","Shin, Hyoung Shik"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32153144","week":"202011|Mar 09 - Mar 15","doi":"10.3947/ic.2020.52.1.110","keywords":["covid-19","coronavirus","hypersensitivity pneumonitis","sars-cov-2"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664640874846355457,"score":56.066696},{"pmid":32342675,"title":"COVID-19, A and Hypersensitivity Pneumonitis.","text":["COVID-19, A and Hypersensitivity Pneumonitis.","Infect Chemother","Joob, Beuy","Wiwanikit, Viroj","32342675"],"journal":"Infect Chemother","authors":["Joob, Beuy","Wiwanikit, Viroj"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342675","source":"PubMed","week":"202018|Apr 27 - May 03","link_comment_for":"32153144","weight":0,"_version_":1665351883910283264,"score":53.832222},{"pmid":32317114,"title":"An academic allergy unit during COVID-19 pandemic in Italy.","text":["An academic allergy unit during COVID-19 pandemic in Italy.","J Allergy Clin Immunol","Malipiero, Giacomo","Paoletti, Giovanni","Puggioni, Francesca","Racca, Francesca","Ferri, Sebastian","Marsala, Antonino","Leoncini, Ornella","Porli, Monica","Pieri, Gabriella","Canonica, Giorgio Walter","Heffler, Enrico","32317114"],"journal":"J Allergy Clin Immunol","authors":["Malipiero, Giacomo","Paoletti, Giovanni","Puggioni, Francesca","Racca, Francesca","Ferri, Sebastian","Marsala, Antonino","Leoncini, Ornella","Porli, Monica","Pieri, Gabriella","Canonica, Giorgio Walter","Heffler, Enrico"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317114","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaci.2020.04.003","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664815087774334977,"score":44.99381},{"pmid":32224232,"title":"COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","text":["COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so.","J Allergy Clin Immunol Pract","Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew","32224232"],"abstract":["In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so."],"journal":"J Allergy Clin Immunol Pract","authors":["Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224232","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaip.2020.03.012","keywords":["allergic rhinitis","allergy","allergy immunotherapy","angioedema","asthma","atopic dermatitis","covid-19","food allergy","primary immunodeficiency","sars-cov-2","urticaria","venom allergy"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["United States","Canada"],"countries":["Canada","United States"],"countries_codes":["CAN|Canada","USA|United States"],"_version_":1664640912819486720,"score":42.659153}]}